breast cancer index testing

Release time ：Dec-13,2024

The Breast Cancer Index (BCI) is a molecular diagnostic tool designed to evaluate the risk of recurrence in breast cancer patients and inform treatment decisions. It forecasts the likelihood of breast cancer relapse and patient survival by assessing the expression levels of specific genes within tumor cells.

During a BCI test, the activity levels of several genes associated with breast cancer progression are measured. These include, but are not limited to, ER (estrogen receptor), PR (progesterone receptor), and HER2 (human epidermal growth factor receptor 2). By conducting a comprehensive analysis of the expression levels of these genes, patients can be classified into low-, medium-, or high-risk categories, assisting physicians in devising personalized treatment strategies.

Understanding the results of one's BCI test is crucial for breast cancer patients. It not only aids in a better comprehension of their condition but also empowers them to be part of the decision-making process regarding their treatment. Patients should also vigilantly monitor their health, engage in regular check-ups and follow-ups to promptly identify and address any issues that may arise. Throughout the treatment journey, it is imperative for patients to adhere to their physician's guidance, organize a well-structured treatment plan, maintain a positive outlook, and actively engage in their treatment to enhance both therapeutic outcomes and overall quality of life.